Abstract
Background: In humans elective spine surgery can cause iatrogenic spinal cord injury (SCI). Efforts for neuroprotection have been directed to avoid mechanical injury by using intraoperative monitoring and improving surgical techniques. There is, however, uncertainty regarding the efficacy of neuroprotective drugs.
Study design: Experimental study on the effectiveness of pharmacological neuroprotection in an animal model of spine surgery simulating anticipated mechanically induced neurological damage.
Objective: To compare the efficacy of four drugs to protect against the neurological effects of iatrogenic SCI.
Setting: Research Unit for Neurological Diseases, IMSS-Proyecto Camina, Mexico City, Mexico.
Methods: Erythropoietin, melatonin, cyclosporine-A and methylprednisolone were administered to rats before, during and after controlled spinal cord contusion of mild intensity. Dosage was in accordance with their pharmacokinetic properties and experience gained with experimental SCI. Drug efficacy was assessed by motor function recovery over a period of 6 weeks and by spinal cord morphometry.
Results: Compared with animals treated with saline, the drug-treated groups showed no differences in their locomotor performance, nor in the amount of spared cord tissue. Notably, spontaneous activity was significantly reduced in rats treated with cyclosporine-A.
Conclusion: The neuroprotectant drugs used here perioperatively did not reduce the extent of neurological damage in a model simulating iatrogenic SCI. Therefore, for now, the only protection in elective spine surgery is avoidance of primary injury altogether.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Delank KS, Delank HW, Konig DP, Popken F, Furderer S, Eysel P . Iatrogenic paraplegia in spinal surgery. Arch Orthop Trauma Surg 2005; 125: 33–41.
Costa P, Bruno A, Bonzanino M, Massaro F, Caruso L, Vincenzo I et al. Somatosensory- and motor-evoked potential monitoring during spine and spinal cord surgery. Spinal Cord 2007; 45: 86–91.
Stellar S, Polanyi TG . Lasers in neurosurgery: a historical overview. J Clin Laser Med Surg 1992; 10: 399–411.
Dumont RJ, Okonkwo DO, Verma S, Hurlbert RJ, Boulos PT, Ellegala DB et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001; 24: 254–264.
Baptiste DC, Fehlings MG . Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 2006; 23: 318–334.
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322: 1405–1411.
Hugenholtz H . Methylprednisolone for acute spinal cord injury: not a standard of care. C Med Assoc J 2003; 168: 1145–1146.
Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002; 99: 9450–9455.
Diaz-Ruiz A, Rios C, Duarte I, Correa D, Guizar-Sahagun G, Grijalva I et al. Cyclosporin-A inhibits lipid peroxidation after spinal cord injury in rats. Neurosci Lett 1999; 266: 61–64.
Okonkwo DO, Melon DE, Pellicane AJ, Mutlu LK, Rubin DG, Stone JR et al. Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat. NeuroReport 2003; 14: 463–466.
Ibarra A, Hernandez E, Lomeli J, Pineda D, Buenrostro M, Martinon S et al. Cyclosporin-A enhances non-functional axonal growing after complete spinal cord transection. Brain Res 2007; 1149: 200–209.
Cayli SR, Kocak A, Yilmaz U, Tekiner A, Erbil M, Ozturk C et al. Effect of combined treatment with melatonin and methylprednisolone on neurological recovery after experimental spinal cord injury. Eur Spine J 2004; 13: 724–732.
Yoon WH, Park SJ, Kim IC, Lee MG . Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 1997; 96: 227–240.
Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D . Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res 1997; 22: 45–51.
Ibarra A, Reyes J, Martinez S, Correa D, Guizar-Sahagun G, Grijalva I et al. Use of cyclosporin-A in experimental spinal cord injury: design of a dosing strategy to maintain therapeutic levels. J Neurotrauma 1996; 13: 569–572.
Basso DM . Behavioral testing after spinal cord injury: congruities, complexities, and controversies. J Neurotrauma 2004; 21: 395–404.
Mills CD, Johnson KM, Hulsebosch CE . Role of group II and group III metabotropic glutamate receptors in spinal cord injury. Exp Neurol 2002; 173: 153–167.
Streit WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT . Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol 1998; 152: 74–87.
Bolanos JP, Garcia-Nogales P, Almeida A . Provoking neuroprotection by peroxynitrite. Curr Pharm Des 2004; 10: 867–877.
Diaz-Ruiz A, Vergara P, Perez-Severiano F, Segovia J, Guizar-Sahagun G, Ibarra A et al. Cyclosporin-A inhibits constitutive nitric oxide synthase activity and neuronal and endothelial nitric oxide synthase expressions after spinal cord injury in rats. Neurochem Res 2005; 30: 245–251.
Acknowledgements
We thank Francisco Márquez for his invaluable assistance with histology techniques.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guízar-Sahagún, G., Rodríguez-Balderas, C., Franco-Bourland, R. et al. Lack of neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions. Spinal Cord 47, 156–160 (2009). https://doi.org/10.1038/sc.2008.85
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2008.85
